Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease.
about
A predicted binding site for cholesterol on the GABAA receptorTau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments.ProNGF\NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic miceSK3 Channel Overexpression in Mice Causes Hippocampal Shrinkage Associated with Cognitive Impairments.Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.High-resolution bioelectrical imaging of Aβ-induced network dysfunction on CMOS-MEAs for neurotoxicity and rescue studies.Chronic treatment with anesthetic propofol improves cognitive function and attenuates caspase activation in both aged and Alzheimer's disease transgenic miceα2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.Rapid Throughput Analysis of GABAA Receptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye.Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation.Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndromeTrisomy 21 and early brain developmentRe-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.Loss of functional GABA(A) receptors in the Alzheimer diseased brain.Age-related changes in slow wave activity rise time and NREM sleep EEG with and without zolpidem in healthy young and older adultsAberrant dendritic excitability: a common pathophysiology in CNS disorders affecting memory?Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down SyndromeShort-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome.Discovery of novel non-synonymous SNP variants in 988 candidate genes from 6 centenarians by target capture and next-generation sequencing.Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.The GABAergic Hypothesis for Cognitive Disabilities in Down SyndromeCombining two repurposed drugs as a promising approach for Alzheimer's disease therapyPentameric Ligand-gated Ion Channels : Insights from Computation.The space where aging acts: focus on the GABAergic synapseTowards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndromeRapid and reliable quantitation of amino acids and myo-inositol in mouse brain by high performance liquid chromatography and tandem mass spectrometry.Bidirectional Regulation of Aggression in Mice by Hippocampal Alpha-7 Nicotinic Acetylcholine Receptors.Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers.Modeling Down Syndrome with Patient iPSCs Reveals Cellular and Migration Deficits of GABAergic Neurons.Genome-wide association study identifies two loci influencing plasma neurofilament light levels.Novel Quantitative Analyses of Spontaneous Synaptic Events in Cortical Pyramidal Cells Reveal Subtle Parvalbumin-Expressing Interneuron Dysfunction in a Knock-In Mouse Model of Alzheimer's Disease
P2860
Q28239688-A86A2E82-7D9A-40CB-AF9E-12EE1F1D79B6Q30444295-BAC60001-F6F4-46B6-92EB-F3D9A4EC0F05Q30541267-DC25500F-11AE-41F3-B7E1-C0E6970CDC0FQ30838734-28C62A20-DCC9-4D95-A235-8216A4DA816EQ33659830-2471A161-B4B6-45F1-BEEC-868BCBEF2DF3Q33732756-2844609D-8F14-4CA0-B3BB-E11EF9E82B22Q33807350-2FB094EA-578F-497A-A2C2-E8CAA1EA1A94Q34295813-0770E4DA-D183-4C8C-BFEF-52C83D77F409Q34555539-28921D7F-F523-4904-98A0-2C41FA87DBCBQ35015325-2A85DCCD-CAC1-4C23-9DE6-B6956BB2956BQ35632680-48748DF7-A192-4EC7-B51A-CA28896FA301Q35740129-4ECB7432-5491-437E-A60C-27DBE5A8EFE3Q35813037-4A1A51C8-CBE6-46EE-ADCF-91CEECAF8140Q36056348-5413CB4F-070D-4A63-9BDE-FBCA9D9A6212Q36191490-1A6B680B-F4C7-4E20-8331-9AEA5CE59F63Q36393590-0911709A-B922-46A4-BFF4-19964DDE8EACQ36399166-AF5950F7-EB1F-4A9A-9D92-DB07E63F47CAQ36965872-0DFFEDC1-618F-44AF-B45C-29BF25C77E75Q37209783-7BD3D7FC-FC4F-4FCD-8D4D-AD4F1EBC916BQ37404222-98ED29AC-05E2-4849-BA0B-1078A6F4D680Q37683060-1709D325-C0E8-4C5D-8947-B6209793BAE1Q37736317-0DD193E3-E499-48DA-9FDC-D4279A6627E4Q38452843-64C793F5-C10F-4FD9-90BD-70C5D1693715Q39301908-84EF5C20-F2B2-4C64-9F4C-1CB0650EEC07Q41574564-43ADB441-CB78-4F9B-B6CB-87285283FDEAQ41811378-27C6AD8D-ABE7-4E7F-9F32-6BB26FD7A844Q42552773-4785D781-7E71-48FC-BE80-946C004AC513Q47623477-FF0685F7-A631-4DEC-9F1D-8A809BF20ADCQ47937645-8ACEFAF4-0895-4745-BCC5-1C4DBCF56968Q51734792-7A854434-7272-4A72-A17F-EDBC95AA6B41Q55146363-2E1B0DFD-7860-443F-83DD-5DF70224E783Q58787421-61697C54-E2F3-4799-B0A5-C1237849935A
P2860
Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Implications for treatment: GA ...... drome and Alzheimer's disease.
@ast
Implications for treatment: GA ...... drome and Alzheimer's disease.
@en
type
label
Implications for treatment: GA ...... drome and Alzheimer's disease.
@ast
Implications for treatment: GA ...... drome and Alzheimer's disease.
@en
prefLabel
Implications for treatment: GA ...... drome and Alzheimer's disease.
@ast
Implications for treatment: GA ...... drome and Alzheimer's disease.
@en
P2860
P1476
Implications for treatment: GA ...... drome and Alzheimer's disease.
@en
P2093
Robert A Rissman
William C Mobley
P2860
P304
P356
10.1111/J.1471-4159.2011.07237.X
P407
P577
2011-03-28T00:00:00Z